Registry for patients with BCR-ABL1-negative myeloid neoplasms

German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)

This study is collecting information and samples from patients with a specific type of blood cancer to better understand the disease and how it affects their lives.

Quick facts

• Study type: Observational
• Enrollment: 2172 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University of Ulm (other)
• Locations: 30 sites (Augsburg and 29 other locations)
• Trial ID: NCT03125707 on ClinicalTrials.gov

What this trial studies

This registry aims to collect data from a large cohort of patients diagnosed with BCR-ABL1-negative myeloid neoplasms, following the WHO classification. It involves the storage of various biological samples, including bone marrow and blood, for future morphologic and genetic analyses. The study will assess clinical characteristics, outcomes, and quality of life, while also correlating biological features with clinical data to identify prognostic and predictive markers. This observational approach will enhance understanding of the disease and its impact on patients.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older diagnosed with BCR-ABL1-negative myeloid neoplasms.

Not a fit: Patients with severe neurological or psychiatric disorders that prevent informed consent will not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could lead to improved understanding and management of BCR-ABL1-negative myeloid neoplasms, ultimately enhancing patient care.

How similar studies have performed: Other registries focusing on myeloid neoplasms have shown success in improving patient outcomes and understanding of the disease.

Eligibility criteria

Inclusion Criteria:

Both female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry:

* Patients with BCR-ABL 1-myeloid neoplasia according to WHO classification or IWG MRI criteria
* Age ≥ 18 years. There is no upper age limit.
* Signed written informed consent.

Exclusion Criteria:

* Severe neurological or psychiatric disorder interfering with ability to give an informed consent
* No consent for registration, storage and handling of the personal data

Where this trial is running

Augsburg and 29 other locations

• Hämatologische Onkologie Praxis Augsburg — Augsburg, Germany (RECRUITING)
• Klinikum Augsburg — Augsburg, Germany (RECRUITING)
• Helios Klinikum, Bad Saarow — Bad Saarow, Germany (RECRUITING)
• Klinikum Mittelbaden — Baden-Baden, Germany (RECRUITING)
• MVZ Klinikum Coburg — Coburg, Germany (RECRUITING)
• Donauwörth, Onko-Medeor — Donauwörth, Germany (RECRUITING)
• Onkologie, BAG, Dresden — Dresden, Germany (RECRUITING)
• Onkologie Erding — Erding, Germany (RECRUITING)
• Universitätsklinikum Freiburg — Freiburg im Breisgau, Germany (RECRUITING)
• Alb Fils Kliniken Göppingen — Göppingen, Germany (RECRUITING)
• Universitätsklinikum Greifswald — Greifswald, Germany (RECRUITING)
• Onkologische Praxis, Heidelberg — Heidelberg, Germany (WITHDRAWN)
• Onkologische Schwerpunktpraxis, Heilbronn — Heilbronn, Germany (WITHDRAWN)
• Marienhospital Bochum-Herne — Herne, Germany (RECRUITING)
• Universitätsklinikum Jena — Jena, Germany (RECRUITING)
• Klinikum Kempten-Oberallgäu gGmbH — Kempten, Germany (RECRUITING)
• Landshut VK&K Studien GbR — Landshut, Germany (RECRUITING)
• Leer, Studienzentrum Unter Ems — Leer, Germany (ACTIVE_NOT_RECRUITING)
• Universitätsklinikum Leipzig — Leipzig, Germany (RECRUITING)
• Universitätsklinikum Magdeburg — Magdeburg, Germany (RECRUITING)
• Universitätsklinikum Mannheim — Mannheim, Germany (RECRUITING)
• Mannheim, Onkologiepraxis — Mannheim, Germany (RECRUITING)
• Memmingen, Onkologiepraxis — Memmingen, Germany (RECRUITING)
• Mühlenkreiskliniken Minden — Minden, Germany (RECRUITING)
• Stauferklinikum Schwäbisch Gmünd — Mutlangen, Germany (RECRUITING)
• Diakonie-Klinikum Stuttgart — Stuttgart, Germany (RECRUITING)
• Stuttgart, MVZ am RBK — Stuttgart, Germany (RECRUITING)
• Universitätsklinikum Ulm — Ulm, Germany (RECRUITING)
• Rems-Murr-Kliniken Winnenden — Winnenden, Germany (RECRUITING)
• Würzburg / Kitzingen, Gemeinschaftspraxis Dr. Schlag — Würzburg, Germany (RECRUITING)

Study contacts

• Study coordinator: Frank Stegelmann, Dr.

Conditions: BCR-ABL1-Negative Myeloid Neoplasms